Medicinova, Inc. · NASDAQ:MNOV

Medicinova — Investor Presentation (March 2025)

17 slides from Medicinova's investor presentation, March 2025

  1. Slide 1: MediciNova Corporate Presentation

    MediciNova Corporate Presentation March 2025

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements in this presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding M

  3. Slide 3: MediciNova Overview

    MediciNova Overview ✓ US Office: San Diego; Japan Office: Tokyo • Dual listed in TSE JASDAQ (4875) and NASDAQ (MNOV) ✓ Biopharma company developing late-stage drug candidate • Multiple late-stage pipelines (Phase 2/3, Phase 2) • Well-established safety profile ✓ Focused on unmet medical needs • MN-1

  4. Slide 4: MNOV Core Pipelines

    MNOV Core Pipelines Indication Phase 1 Phase 2 Phase 3 MN-166 (ibudilast) ALS* (Amyotrophic Lateral Sclerosis) * Orphan disease, Fast Track Brain Tumor (Glioblastoma** Brain metastasis) ** Fast Track Acute Lung Injury / Sever Pneumonia MN-001 (tipelukast) 5 Type 2 DM+ Hyper TG + NAFLD SAR 444836 (AA

  5. Slide 5: Academia Partnered Programs

    Academia Partnered Programs • All non-core programs are FULLY FUNDED by public/government agencies, run by academia researchers from reputable institutions in US, UK, Australia, and Canada • Upon completion MNOV has full rights for regulatory applications with ZERO development expenses • MNOV then h

  6. Slide 6: MN-166 Ibudilast

    MN-166 Ibudilast @ 6 © MediciNova, Inc. MEDICINOVA

  7. Slide 7: MN-166 Overview

    MN-166 Overview CODE MN-166 Description Small Molecule Chemical Name Ibudilast Administrate Route Oral I.V. injection Mechanism of Action Multiple MOAs (MOA) MIF (macrophage inhibitory factor) inhibitor PDE (phosphodiesterase) 3, 4, 10, and 11 inhibitor TLR4 ( Toll-Like-Receptor 4) inhibitor Clinica

  8. Slide 8: Positive outcome from first Phase 2 ALS study

    Positive outcome from first Phase 2 ALS study (MN-166-ALS-1201) Study Summary • Single-center (PI: Dr. Brooks, Carolina Neuromuscular ALS MDA Center), R(1:2), PCT, DB followed by OLE • Target ALS patients (ALS history ~ 5 years), on Riluzole treatment • Treatment: 60 mg/day MN-166 or Placebo X 6 mon

  9. Slide 9: Ongoing Phase 2/3 ALS study

    Ongoing Phase 2/3 ALS study (COMBAT-ALS / MN-166-ALS-2301) Study Sites : Multi-centers in US and Canada Study Design : R (1:1), PCT, DB study followed by OLE Target Patients: Early-stage ALS (ALS history within 18 mo ) Dose : 100mg/day or placebo Treatment Duration : 12-mo DB, 6-mo OLE Size: N=230 (

  10. Slide 10: Upcoming NIH funding Expand Access ALS study

    Upcoming NIH funding Expand Access ALS study (SEA-NOBI-ALS) Sponsor : NIH NINDS (National Institute of Neurological Disorders and Strokes ) Funding Amount : $ 22 M Lead PI : Mayo Clinic Dr. Oskarsson Study Sites : Multi-centers in US (approx. 20 sites) Study Design: Open-Label study Target Patients:

  11. Slide 11: Positive outcome from first Phase 1/2 GBM study

    Positive outcome from first Phase 1/2 GBM study (MN-166-GBM-1201 ) Study Summary • Single-center (PI: Dr. Wen, Dana-Farber Cancer Institute), Open-Label study • GBM patients on Standard of Care (TMZ chemo-therapy) • Treatment: 100 mg/day MN-166 with up to TMZ chemo-therapy 12 cycles • Total 62 patie

  12. Slide 12: Positive outcome from first Phase 2 COVID-19 ARDS risk study

    Positive outcome from first Phase 2 COVID-19 ARDS risk study (MN-166-COVID19-201 ) Study Summary • Multi-center (PI: Dr. Wyler Dr. Sauler), R(1:1), RCT, DB • Severe hospitalized COVID-19 patients with ARDS risk factor (i.e. Age, Medical History, Obesity) • Treatment: 100 mg/day or placebo 7 days • T

  13. Slide 13: MN-001 Tipelukast

    MN-001 ~. @& Tipelukast " < ‘S 13 © MediciNova, Inc.

  14. Slide 14: MN-001 Overview

    MN-001 Overview CODE MN-001 Description Small Molecule Chemical Name Tipelukast Administrate Route Oral Mechanism of Action Multiple MOA (MOA) Leukotriene & 5-lipoxygenase (5-LO) pathway inhibitor PDE (phosphodiesterase) 3,4 inhibitor Clinical effect Anti-inflammation Reduce serum triglyceride Reduc

  15. Slide 15: Positive outcome from first Phase 2 NAFLD/NASH + HyperTG study

    Positive outcome from first Phase 2 NAFLD/ NASH + HyperTG study (MN-001-NATG-201) Study Summary • Multi-center, Open-Label study in US • NAFLD/NASH patients with Hyper TG • Treatment : 250 mg/day x 4 weeks followed by 500 mg/day x 8 weeks • Total 19 patients enrolled Serum TG level (mg/dL) Serum HDL

  16. Slide 16: Ongoing Phase 2 HyperTG + T2DM + NAFLD study

    Ongoing Phase 2 HyperTG + T2DM + NAFLD study (MN-001-NATG-202) Study Sites : 2 centers in US Study Design : R (1:1), PCT, DB study • Jubilee Clinical Research Center o PI: Dr. Shin • South Texas Research Institute o PI: Dr. Patil Target Patients : HyperTG + T2DM+ NAFLD Dose : 500mg/day or placebo Tr

  17. Slide 17: Thank you!

    CONTACT: Thank you ! Yuichi Iwaki, MD, PhD David H. Crean, PhD CEO/President Chief Business Officer iwaki@medicinova.com crean@medicinova.com 17 © MediciNova, Inc.

MediciNova — Investor Presentation (March 2025) on 6ix